T
TriSalus Life Sciences
Home - Surefire Medical, Inc.
About TriSalus Life Sciences
TriSalus Life Sciences, originally known as Surefire Medical, was founded with a vision to revolutionize the treatment landscape for liver and pancreatic tumors. The company was established by a team of dedicated professionals, including Dr. Steven Hetts, who played a pivotal role in its inception.
Surefire Medical initially focused on developing innovative infusion systems designed to enhance the delivery of therapeutic agents directly to tumors. This approach aimed to improve the efficacy of treatments while minimizing systemic exposure and side effects. The company's technology quickly gained traction, leading to significant interest from the medical community and investors alike.
In a strategic move to expand its capabilities and market reach, Surefire Medical underwent a rebranding to become TriSalus Life Sciences. This transition marked a new chapter in the company's journey, emphasizing its commitment to advancing immunotherapy and drug delivery solutions. The rebranding also aligned with a broader strategy to integrate cutting-edge science with practical medical applications.
TriSalus Life Sciences has not only attracted substantial funding to support its research and development efforts but has also formed strategic partnerships to accelerate its growth. These collaborations have been instrumental in advancing the company's mission to provide innovative solutions for challenging medical conditions.
Today, TriSalus Life Sciences stands at the forefront of medical innovation, driven by a relentless pursuit of improving patient outcomes through targeted therapies. The company's journey reflects a blend of visionary leadership, scientific excellence, and a commitment to transforming the landscape of cancer treatment.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Westminster, United States
- Listing
- IPO 2021
- Employees
- 123
- Open positions
- None listed
- Dealroom signal
- 51.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Hardware
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $40M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2025 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $45M | 0% |
| 2025 | $45M | +53.7% |
| 2024 | $29M | +58.8% |
| 2023 | $19M | +49.3% |
| 2022 | $12M | +47.6% |
| 2021 | $8.4M | +50.8% |
| 2020 | $5.6M | — |
Growth signals
Latest recorded traffic for TriSalus Life Sciences is 0 monthly website visits. TriSalus Life Sciences's team grew 11.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- PGPartisan Management Group
- HVHigh Country Venture
MCG Capital- NMNantahala Capital Management
Series B and later2 investors entered at this stage
Tullis Health Investors
OrbiMed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TriSalus Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TriSalus Life Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.